opdivo lung cancer
ESMO 2023: Bristol Myers Squibb’s Opdivo Plus Chemotherapy Improves Survival in Resectable NSCLC: CheckMate -816 Trial
Anika Sharma
ESMO 2023: Abstract ID 1261O Treating early-stage NSCLC presents numerous obstacles, given the restricted therapeutic alternatives available. In this landscape, ...
